Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with broad range of AML subtypes in combination with natural killer cells.

Chip-based platform for dynamic analysis of NK cell cytolysis mediated by a triplebody.

Dual-targeting triplebody 33-3-19 mediates selective lysis of biphenotypic CD19+ CD33+ leukemia cells.

CD19-specific triplebody SPM-1 engages NK and γδ  T cells for rapid and efficient lysis of malignant B-lymphoid cells.

T cell-recruiting triplebody 19-3-19 mediates serial lysis of malignant B-lymphoid cells by a single T cell.

A dual-targeting triplebody mediates preferential redirected lysis of antigen double-positive over single-positive leukemic cells.

NK cells from an AML patient have recovered in remission and reached comparable cytolytic activity to that of a healthy monozygotic twin mediated by the single-chain triplebody SPM-2.

Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16.

A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukemia cells by dual-targeting.

A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells.